Tadalafil Chewable Tablets

Available Dosage Strengths

25 mg

Want to Prescribe?

Disclaimer: Images are for reference only; actual products may vary.

Product Overview

Description

Tadalafil, a phosphodiesterase type 5 (PDE5) inhibitor, has a mean terminal half-life of over 17 hours. This half-life is much longer than other PDE-5 inhibitors. This half-life allows for once-daily or on-demand dosing. The drug is indicated for the treatment of pulmonary arterial hypertension (PAH), erectile dysfunction (ED), benign prostatic hypertrophy (BPH), or the concurrent treatment of ED and BPH.^1,2

Mechanism of Action

Phosphodiesterase (PDE) has many isoforms and is an enzyme that has many functions in the body including degrading the effect of cyclic adenosine monophosphate (cAMP) and cyclic guanosine monophosphate (cGMP). PDE5 is an enzyme that is found in many parts of the body including in the smooth muscle of the corpus cavernosum, prostate, bladder, the vascular and visceral smooth muscle, skeletal muscle, urethra, platelets, kidney, lung, cerebellum, heart, liver, testis, seminal vesicle, and pancreas. Tadalafil is a selective inhibitor of PDE5, the enzyme responsible for the degradation of cGMP. The drug has selective activity on PDE5 than other phosphodiesterase isoforms. Tadalafil activity on PDE5 is more than 10,000-fold more than for PDE1, PDE2, PDE4, and PDE7 enzymes. Increased cGMP leads to smooth muscle relaxation in the corpus cavernosum which can help in maintaining an erection.^1,2,3

Adverse Reactions

Common¹

Headache
Dyspepsia
Flushing
Back pain and myalgia (typically delayed onset, resolving within 48 hours)
Nasal congestion
Pain in limbs

Contraindications & Precautions

Contraindications^1,2

Known hypersensitivity to tadalafil or tablet excipients
Use of nitrates and guanylate cyclase (GC) stimulators therapy, such as riociguat due to risk of life-threatening hypotension

Precautions^1,2

Use with caution in patients with:
Severe hepatic impairment (Child-Pugh Class C)
Severe renal impairment (creatinine clearance <30 mL/min)
Retinitis pigmentosa (rare inherited retinal disorder)
History of NAION (non-arteritic anterior ischemic optic neuropathy)
Recent history of myocardial infarction, stroke, or unstable angina

Storage

Store at 20°C to 25°C (68°F to 77°F). Protect from light, moisture, and heat.¹

References

Tadalafil Prescribing Information – Eli Lilly. www.accessdata.fda.gov/drugsatfda_docs/label/2011/021368s20s21lbl.pdf Revised October 2011. Accessed May 31, 2025
Clinical Pharmacology Tadalafil clinical monograph 2025 https://www.clinicalkey.com/pharmacology/
Padda IS, Tripp J. Phosphodiesterase Inhibitors. [Updated 2023 Jun 26]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025 Jan-. Available from: https://www.ncbi.nlm.nih.gov/books/NBK559276/

Disclaimer

This sheet is a summary. It may not cover all possible drug information about this product. Call your doctor for medical advice and/or about side effects. You may report side effects to the FDA at 1-800-FDA-1088. A Wells Pharmacy Network pharmacist will be happy to answer any questions. For consultation, please call 1-800-622-4510.